Drug-eluting beads-transcatheter arterial chemoembolization with or without iodine-125 treatment is effective and tolerable in treating advanced non-small cell lung cancer patients: a pilot study

Zhongwei Zhao, Jianfei Tu, Xiaoxi Fan, Jingjing Song, Fazong Wu, Xihui Ying, Jianting Mao, Jiansong Ji
2020 Translational Cancer Research  
This study aimed to explore the efficacy and safety of drug-eluting beads-transcatheter arterial chemoembolization (DEB-TACE) with or without iodine-125 ( 125 I) seed implantation in treating advanced non-small cell lung cancer (NSCLC) patients. Methods: A total of 25 advanced NSCLC patients underwent DEB-TACE were consecutively enrolled, among which 17 cases also received 125 I seed implantation post DEB-TACE treatment. Treatment response, overall survival (OS), biochemical indexes and safety
more » ... indexes and safety profiles were recorded and analyzed. Results: Zero (0.0%), 13 (54.2%), 9 (37.5%) and 2 (8.3%) patients realized complete response (CR), partial response (PR), stable disease (SD) and progression disease (PD) respectively, and the objective response rate (ORR) and disease control rate (DCR) were 54.2% and 91.7%. The median OS was 12.6 (95% CI: 7.8-17.5) months. No difference of treatment response or OS was observed between DEB-TACE treatment alone and DEB-TACE plus 125 I seed implantation. Predictive factors analysis revealed that tumor size correlated with worse OS. Besides, chest distress grade and dyspnea grade were decreased after DEB-TACE procedure, while clinical symptoms were not changed after 125 I seed implantation. The common adverse events (AEs) were fever (32.0%), pain (12.0%) by DEB-TACE treatment, and common AE was pain (26.7%) by 125 I seed implantation. Conclusions: DEB-TACE with or without 125 I seed implantation is effective and tolerable in treating advanced NSCLC patients. Pain, n (%) 3 (12.0) Fever, n (%) 8 (32.0) Nausea, n (%) 1 (4.0) Vomit, n (%) 1 (4.0) Others, n (%) 8 (32.0) Data were presented as count (percentage). DEB-TACE, drugeluting beads-transcatheter arterial chemoembolization.
doi:10.21037/tcr.2020.03.64 fatcat:ethz5wtcvvgllhgtql5ksn42jq